U0126
Modify Date: 2024-01-01 23:05:29
U0126 structure
|
Common Name | U0126 | ||
|---|---|---|---|---|
| CAS Number | 109511-58-2 | Molecular Weight | 380.490 | |
| Density | 1.4±0.1 g/cm3 | Boiling Point | 565.1±50.0 °C at 760 mmHg | |
| Molecular Formula | C18H16N6S2 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | 295.6±30.1 °C | |
Use of U0126U0126 is a potent, non-ATP competitive and selective MEK1 and MEK2 inhibitor, with IC50s of 72 nM and 58 nM, respectively. U0126 is an autophagy and mitophagy inhibitor[1][2][3][4]. |
| Name | (2Z,3Z)-bis{amino[(2-aminophenyl)sulfanyl]methylidene}butanedinitrile |
|---|---|
| Synonym | More Synonyms |
| Description | U0126 is a potent, non-ATP competitive and selective MEK1 and MEK2 inhibitor, with IC50s of 72 nM and 58 nM, respectively. U0126 is an autophagy and mitophagy inhibitor[1][2][3][4]. |
|---|---|
| Related Catalog | |
| Target |
MEK2:60 nM (IC50) MEK1:70 nM (IC50) |
| In Vitro | Treatment with U0126 efficiently reduces progeny virus titers of all tested strains in A549 cells. While nM concentrations of U0126 are efficient to reduce H1N1v and H5N1 (MB1), μM concentrations of U0126 are required to reduce the virus titer of H5N1 (GSB) and H7N7. The EC50 values for U0126-EtOH against H1N1v are 1.2±0.4 μM in A549 cells and 74.7±1.0 μM in MDCKII cells[2]. Rat hepatocarcinoma cells (FAO) stimulated by fetal calf serum (FCS) exhibits a significant proportion in S phase (32.62%) whereas U0126 strongly decreases the proportion of cells in S phase (9.92%) and increases the proportion of cells in G0-G1 phase and to a lesser extent in G2/M[3]. Cell Viability Assay[2] Cell Line: A549 and MDCK II cells. Concentration: 0.001-1000 μM. Incubation Time: 48 h. Result: The EC50 values for U0126 against H1N1v were 1.2 ± 0.4 μM in A549 cells and 74.7 ± 1.0 μM in MDCKII cells |
| In Vivo | Mice are treated daily with U0126-EtOH (U0126; i.p., 10.5 mg/kg). In control experiment, tumor sizes are constant or slightly increase all over the kinetic. At the opposite, in all U0126-EtOH experiments, engraftment and early tumor growth are significantly decreased. Furthermore, a 60-70% reduction in the volume of tumors treated with U0126-EtOH is obtained 9 days after injection and thereafter[3]. Rats are subjected to 120 minutes transient middle cerebral artery occlusion (tMCAO) and thereafter treated with the U0126-EtOH (U0126; i.p., 30 mg/kg) at 0 and 24 hours of reperfusion. After treatment with U0126-EtOH, the vasoconstriction to S6c is markedly reduced[4]. Animal Model: Athymic female nude mice (SWISS, nu/nu)[3]. Dosage: 10.5 mg/kg. Administration: Intraperitoneal injection daily. Result: Inhibited tumor growth. Animal Model: Twelve-week-old female Wistar rats (250 to 265 g) [4]. Dosage: 30 mg/kg. Administration: Intraperitoneally. Result: The vasoconstriction to S6c is markedly reduced. |
| References |
| Density | 1.4±0.1 g/cm3 |
|---|---|
| Boiling Point | 565.1±50.0 °C at 760 mmHg |
| Molecular Formula | C18H16N6S2 |
| Molecular Weight | 380.490 |
| Flash Point | 295.6±30.1 °C |
| Exact Mass | 380.087799 |
| PSA | 202.26000 |
| LogP | -1.07 |
| Vapour Pressure | 0.0±1.5 mmHg at 25°C |
| Index of Refraction | 1.762 |
|
~%
U0126 CAS#:109511-58-2 |
| Literature: US2779780 , ; |
| Precursor 2 | |
|---|---|
| DownStream 0 | |
| (2Z,3Z)-2,3-bis[amino-(2-aminophenyl)sulfanylmethylidene]butanedinitrile |
| Butanedinitrile, 2,3-bis[amino[(2-aminophenyl)thio]methylene]-, (2Z,3Z)- |
| U 0126 |
| (2Z,3Z)-Bis{amino[(2-aminophenyl)sulfanyl]methylene}succinonitrile |
| (2Z,3Z)-bis{amino[(2-aminophenyl)sulfanyl]methylidene}butanedinitrile |
| U0126 |
| U-0126 |